{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:47:04Z","timestamp":1791996424542,"version":"4.4.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-026-06332-0","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T08:58:49Z","timestamp":1784278729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["NTRK fusion in metastatic castration-resistant prostate cancer treated with entrectinib: a case report"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4224-5084","authenticated-orcid":false,"given":"Shuichi","family":"Tatarano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Mitsuke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Osako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Inoguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutoshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Enokida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"6332_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/15384047.2018.1523849","volume":"20","author":"S Ikeda","year":"2019","unstructured":"Ikeda S, Elkin SK, Tomson BN, et al. Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. Cancer Biol Ther. 2019;20:219\u201326.","journal-title":"Cancer Biol Ther"},{"key":"6332_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092552","volume":"15","author":"CM Gillette","year":"2023","unstructured":"Gillette CM, Yette GA, Cramer SD, et al. Management of advanced prostate cancer in the precision oncology era. Cancers (Basel). 2023;15: 2552.","journal-title":"Cancers (Basel)"},{"key":"6332_CR3","doi-asserted-by":"publisher","first-page":"175883592097561","DOI":"10.1177\/1758835920975613","volume":"12","author":"A Forsythe","year":"2020","unstructured":"Forsythe A, Zhang W, Phillip Strauss U, et al. A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors. Adv Med Oncol. 2020;12:1758835920975613.","journal-title":"Adv Med Oncol"},{"key":"6332_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41698-021-00206-y","volume":"5","author":"CB Westphalen","year":"2021","unstructured":"Westphalen CB, Krebs MG, Le Tourneau C, et al. Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol. 2021;5:69.","journal-title":"NPJ Precis Oncol"},{"key":"6332_CR5","doi-asserted-by":"publisher","first-page":"viii22","DOI":"10.1093\/annonc\/mdy269.073","volume":"29","author":"Q Ling","year":"2018","unstructured":"Ling Q, Li B, Wu X, et al. The landscape of NTRK fusions in Chinese patients with solid tumor. Ann Oncol. 2018;29:viii22-23.","journal-title":"Ann Oncol"},{"key":"6332_CR6","first-page":"341","volume":"7","author":"YA Yeh","year":"2019","unstructured":"Yeh YA, Yang S, Constantinescu M, et al. Prostatic adenocarcinoma with novel NTRK3 gene Fusion: a case report. Am J Clin Exp Urol. 2019;7:341\u20135.","journal-title":"Am J Clin Exp Urol"},{"key":"6332_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731\u20139.","journal-title":"N Engl J Med"},{"key":"6332_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, Dubois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2020;21:531\u201340.","journal-title":"Lancet Oncol"},{"key":"6332_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol. 2020;21:271\u201382.","journal-title":"Lancet Oncol"},{"key":"6332_CR10","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","volume":"28","author":"GD Demetri","year":"2022","unstructured":"Demetri GD, De Braud F, Drilon A, et al. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res. 2022;28:1302\u201312.","journal-title":"Clin Cancer Res"},{"key":"6332_CR11","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1002\/pros.20443","volume":"66","author":"T Kikugawa","year":"2006","unstructured":"Kikugawa T, Kinugasa Y, Shiraishi K, et al. PLZF regulates PBX1 transcription and PBX1-HOXC8 complex leads to androgen-independent prostate cancer proliferation. Prostate. 2006;66:1092\u20139.","journal-title":"Prostate"},{"key":"6332_CR12","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1074\/jbc.RA118.006057","volume":"294","author":"Y Liu","year":"2019","unstructured":"Liu Y, Xu X, Lin P, et al. Inhibition of the deubiquitinase USP9X induces pre-B cell homeobox 1 (PBX1) degradation and thereby stimulates prostate cancer cell apoptosis. J Biol Chem. 2019;294:4572\u201382.","journal-title":"J Biol Chem"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06332-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06332-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06332-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:04:55Z","timestamp":1791993895000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06332-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6332"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-06332-0","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"23 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research complied with the guidelines for human studies following the World Medical Association Declaration of Helsinki. The authors obtained consent from the ethics committee of Kagoshima University (#230059).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"617"}}